Skip to content
Search AI Powered

Latest Stories

Protect life sciences in upcoming Budget - New APPG urges Chancellor

Protect life sciences in upcoming Budget - New APPG urges Chancellor

MPs and peers underscore that the UK’s life sciences sector has incredible potential to become a global hub for cutting-edge, life-saving innovations 

The newly-formed All-Party Parliamentary Group (APPG) for Life Sciences has written to Chancellor of the Exchequer Rachel Jane Reeves, urging her to protect and promote the life sciences sector in the government's first Budget.

The group, which includes MPs and peers, convened for its first meeting in Parliament on Tuesday (15 October) to discuss the steps the Labour government should take to ensure that the UK remains a global leader in life sciences research and commercialisation.


Following the meeting, the group sent a letter to the Chancellor, expressing their support for the Labour Party's life sciences strategy, A Prescription for Growth, which was published before the general election.

They urged the Chancellor to maintain government funding for life sciences research and manufacturing, as well as the tax reliefs that encourage investment, in the  Budget set for 30 October.

Kit Malthouse MP, chair of the APPG, emphasised the potential of the life sciences sector, saying, “The Life Sciences sector holds out an incredible promise that the UK can be at the forefront of humanity’s battle with disease and at the same time build a 21st century knowledge-based economy.

“The All-Party Group embraces every aspect of this exciting sector and we hope it will play a part in maintaining the UK as a science super power.”

Pippa Heylings MP, an APPG officer, highlighted the strength of the UK's life sciences ecosystem, noting its potential to become a world-leading hub for cutting-edge, life-saving innovations.

“Harnessing research, technology, AI and genomics whilst collaborating with healthcare providers, this ecosystem can make a breakthrough contribution to people’s lives and to our economy.

“Boosting late-stage funding and infrastructure capacity are critical steps in achieving this ambition,” she stated.

Sadik Al-Hassan MP, another APPG officer, underscored the importance of the life sciences sector for Britain's future, noting that its development is “an important pillar of Britain’s aspiration to lead the global economy in key sectors and provides high quality employment opportunities across the UK.”

“Funding further development in this sector can provide great value for money to taxpayers,” he said.

Baroness Delyth Morgan of Drefelin, also an APPG officer, expressed her delight to be part of this new group stating that it “brings together key leaders in the life sciences ecosystem to champion the huge benefits for patients and society the sector can bring.”

The new APPG is supported by key industry stakeholders, including:

  • The BioIndustry Association (BIA)
  • The Association of Medical Research Charities (AMRC)
  • Cancer Research UK (CRUK)
  • The Association of the British Pharmaceutical Industry (ABPI)
  • The Academy of Medical Sciences, Versus Arthritis
  • The British Heart Foundation
  • The British In Vitro Diagnostic Association (BIVDA)

In 2023, medical research charities invested £1.7 billion in research and development (R&D), while the life sciences industry invested over £9 billion. This funding supports over 26,000 charity-funded researcher jobs in universities and the NHS, as well as over 300,000 industry jobs across the UK.

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less